 Serum erythropoietin levels patients intensive chemotherapy radiotherapy potential role recombinant human erythropoietin rhEpo patients intensive cytotoxic therapy endogenous levels Epo patients bone marrow transplantation BMT Seventeen patients underwent allogeneic BMT underwent autologous BMT average units red blood cells RBCs patient mean RBC transfusion requirement autologous BMT patients allogeneic recipients groups comparable hematocrits Epo levels radioimmunoassay RIA patient baseline serum Epo levels time admission hospital Subsequent samples hours chemotherapy and/or radiotherapy days BMT Hematocrits Hcts patients initial serum creatinine equal mg/dL considerable differences absolute Epo levels individuals characteristic pattern admission hospital initiation cytotoxic therapy average Hct average Epo level mean serum Epo levels day post-BMT mU/mL average Hcts day day post-BMT different average serum Epo levels period day post-BMT mean Epo levels low reference population bone marrow failure normal controls cytotoxic therapy endogenous Epo response weeks post-BMT clinical trials efficacy administration rhEpo treatment anemias cytotoxic therapy